- In the first quarter, sales were 41 029 USD.
- The corporation posted its first-ever positive quarterly performance.
Sangui BioTech International Inc. generated revenues from royalties of USD 41,029 in the first quarter of the fiscal year 2023 (ending on June 30, 2023).
The similar revenue within the same time frame the year before was USD 18,560. When compared to the same three-month period last year, the resultant royalty income climbed by 121% as a consequence of greater sales of the wound spray Granulox.
During the first quarter, operating expenditures dropped by USD 4,872 or 8% to USD 57,231. The aforementioned elements caused the three-month operating deficit to drop from USD 27,341 to USD 16,202.
For the first time, a positive quarterly result of USD 24,934 could be obtained due to the higher exchange rate of the US dollar to the EURO compared to the reporting date of the previous year and the enhanced currency rate gains arising from the valuation of loans denominated in the EURO.
The quarterly result increased by USD 52,851 over the same period the prior year, when there had been a loss of USD 27,917.
The shares of the holding company Sangui BioTech International, Inc. (abbreviated “SGBI”) are traded on the pink market run by OTC Markets Group Inc. The reporting from the companies is up to date, and the management is certified annually.
Aside from the Berlin and Hamburg-Hannover stock exchanges, Sangui shares are also traded on their OTC markets (symbol: SBH).
Its goal is to offer the Sangui group’s businesses funding and access to the financial markets. 90 percent of Sangui BioTech International, Inc.’s assets are held by Sangui BioTech GmbH.